Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Now Rated “Buy” by Wall Street Analysts

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) has been given a consensus recommendation of “Buy” by the twelve brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $46.38.

Several equities analysts recently issued reports on the company. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective for the company. Guggenheim started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, November 6th. They set a “buy” rating and a $59.00 target price on the stock. Wedbush restated an “outperform” rating and set a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st.

View Our Latest Analysis on DMRA

Damora Therapeutics, Inc. Common Stock Price Performance

Damora Therapeutics, Inc. Common Stock stock opened at $21.60 on Monday. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -15.32 and a beta of 1.52. The company’s 50 day simple moving average is $22.19 and its 200 day simple moving average is $25.61. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $15.76 and a fifty-two week high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.12. As a group, analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jennifer Jarrett acquired 12,500 shares of the company’s stock in a transaction that occurred on Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the acquisition, the chief executive officer directly owned 512,500 shares in the company, valued at approximately $10,367,875. The trade was a 2.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DMRA. Braidwell LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. Seven Fleet Capital Management LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $7,398,000. Squarepoint Ops LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $303,000. Finally, Arizona State Retirement System acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $260,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Further Reading

Analyst Recommendations for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.